Fate Therapeutics to Present at Jefferies Cell Therapy Virtual Summit
September 30 2020 - 08:00AM
Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage
biopharmaceutical company dedicated to the development of
programmed cellular immunotherapies for cancer and immune
disorders, today announced that management will participate in a
fireside chat at the Jefferies Cell Therapy Virtual Summit on
Tuesday, October 6, 2020 and 2:30 p.m. E.T.
A live webcast of the presentation will be available through the
investor relations section of the Company's website at
www.fatetherapeutics.com.
About Fate Therapeutics, Inc.Fate Therapeutics
is a clinical-stage biopharmaceutical company dedicated to the
development of first-in-class cellular immunotherapies for cancer
and immune disorders. The Company has established a leadership
position in the clinical development and manufacture of universal,
off-the-shelf cell products using its proprietary induced
pluripotent stem cell (iPSC) product platform. The Company’s
immuno-oncology product candidates include natural killer (NK) cell
and T-cell cancer immunotherapies, which are designed to synergize
with well-established cancer therapies, including immune checkpoint
inhibitors and monoclonal antibodies, and to target
tumor-associated antigens with chimeric antigen receptors (CARs).
The Company’s immuno-regulatory product candidates include
ProTmune™, a pharmacologically modulated, donor cell graft that is
currently being evaluated in a Phase 2 clinical trial for the
prevention of graft-versus-host disease, and a myeloid-derived
suppressor cell immunotherapy for promoting immune tolerance in
patients with immune disorders. Fate Therapeutics is headquartered
in San Diego, CA. For more information, please visit
www.fatetherapeutics.com.
Contact:Christina TartagliaStern Investor
Relations, Inc.212.362.1200christina@sternir.com
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Feb 2024 to Mar 2024
Fate Therapeutics (NASDAQ:FATE)
Historical Stock Chart
From Mar 2023 to Mar 2024